NKG2D CD16 AND FLT3 BINDING PROTEINS
VE6142020000193SUndetermined Publication Date: 2022-02-17DRAGONFLY THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- VE · VE
- Patent Type
- Designs
- Current Assignee / Owner
- DRAGONFLY THERAPEUTICS INC
- Filing Date
- 2020-10-14
- Publication Date
- 2022-02-17
Need to check novelty before this filing date? Find Prior Art
Description
Multispecific binding proteins that bind to the NKG2D CD16 and FLT3 receptors are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of autoimmune diseases or cancer.